These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24672385)

  • 1. The role of 18F-FDG-PET and PET/CT in patients with colorectal liver metastases undergoing selective internal radiation therapy with yttrium-90: a first evidence-based review.
    Annunziata S; Treglia G; Caldarella C; Galiandro F
    ScientificWorldJournal; 2014; 2014():879469. PubMed ID: 24672385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
    Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
    Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
    Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
    J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI.
    Wong CY; Salem R; Raman S; Gates VL; Dworkin HJ
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):815-20. PubMed ID: 12029557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
    Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
    J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT in assessment of colorectal liver metastases: a comprehensive review with emphasis on
    Zirakchian Zadeh M
    Clin Exp Metastasis; 2023 Dec; 40(6):465-491. PubMed ID: 37682423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors.
    Kucuk ON; Soydal C; Lacin S; Ozkan E; Bilgic S
    World J Surg Oncol; 2011 Aug; 9():86. PubMed ID: 21819613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET.
    Lin M; Shon IH; Wilson R; D'Amours SK; Schlaphoff G; Lin P
    Hepatogastroenterology; 2007; 54(75):910-2. PubMed ID: 17591090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 90Y microsphere (TheraSphere) treatment for unresectable colorectal cancer metastases of the liver: response to treatment at targeted doses of 135-150 Gy as measured by [18F]fluorodeoxyglucose positron emission tomography and computed tomographic imaging.
    Lewandowski RJ; Thurston KG; Goin JE; Wong CY; Gates VL; Van Buskirk M; Geschwind JF; Salem R
    J Vasc Interv Radiol; 2005 Dec; 16(12):1641-51. PubMed ID: 16371530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CT.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Tutor C; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):778-87. PubMed ID: 15772860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
    Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
    Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT- versus coregistered FDG-PET/CT-based radiation therapy plans for conformal radiotherapy in colorectal liver metastases: a dosimetric comparison.
    Parlak C; Topkan E; Sonmez S; Onal C; Reyhan M
    Jpn J Radiol; 2012 Oct; 30(8):628-34. PubMed ID: 22744437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.
    van Kessel CS; Buckens CF; van den Bosch MA; van Leeuwen MS; van Hillegersberg R; Verkooijen HM
    Ann Surg Oncol; 2012 Sep; 19(9):2805-13. PubMed ID: 22396005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential FDG PET/CT in 90Y microsphere treatment of unresectable colorectal liver metastases.
    Bienert M; McCook B; Carr BI; Geller DA; Sheetz M; Amesur N; Avril N
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):723. PubMed ID: 15599525
    [No Abstract]   [Full Text] [Related]  

  • 16. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment.
    Niekel MC; Bipat S; Stoker J
    Radiology; 2010 Dec; 257(3):674-84. PubMed ID: 20829538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anatomic versus Metabolic Tumor Response Assessment after Radioembolization Treatment.
    Jongen JMJ; Rosenbaum CENM; Braat MNGJA; van den Bosch MAAJ; Sze DY; Kranenburg O; Borel Rinkes IHM; Lam MGEH; van den Hoven AF
    J Vasc Interv Radiol; 2018 Feb; 29(2):244-253.e2. PubMed ID: 29249594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Yttrium-90 microsphere-selective internal radiation therapy with chemotherapy (chemo-SIRT) for colorectal cancer liver metastases: an in vivo double-arm-controlled phase II trial.
    Gulec SA; Pennington K; Wheeler J; Barot TC; Suthar RR; Hall M; Schwartzentruber D
    Am J Clin Oncol; 2013 Oct; 36(5):455-60. PubMed ID: 22643569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy.
    Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C
    Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.